Skip to main content

UBS Group AG

Position in INVA — Innoviva, Inc.

CIK 1610520 ZURICH, V8

Position in INVA

as of Mar 31, 2026 · filed May 5, 2026
Position Value
$10,184,266
+$25,790 QoQ
Shares Held
437,093
-14.0% QoQ
Ownership
0.592%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 99.0027293962612.ToString("F0")% Shared 0.ToString("F0")% None 0.9972706037387924.ToString("F0")%

Common Shares in INVA Over Time

Shares Held

Position Value (USD)

Derivatives in INVA

reported options exposure · as of Jun 30, 2020
CallValue
$1,479,084
CallShares
105,800
PutValue
$6,990,000
PutShares
500,000

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

UBS Group AG holds $8,307,109,707 across 562 Biotechnology names. INVA ranks #104 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in INVA

Export CSV
29 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $10,184,266 437,093
2025-12-31 $10,158,476 508,178
2025-09-30 $10,445,715 572,368
2025-06-30 $5,060,048 251,869
2025-03-31 $9,886,451 545,309
2024-12-31 $11,736,736 676,469
2024-09-30 $5,954,159 308,346
2024-06-30 $4,574,025 278,904
2024-03-31 $8,264,590 542,296
2023-12-31 $5,736,848 357,659
2023-09-30 $8,136,351 626,355
2023-06-30 $2,462,172 193,415
2023-03-31 $4,817,575 428,229
2022-12-31 $6,145,243 463,792
2022-09-30 $261,793 22,549
2022-06-30 $9,408,097 637,405
2022-03-31 $12,459,348 643,894
2021-12-31 $8,971,793 520,104
2021-09-30 $6,701,277 401,034
2021-06-30 $7,797,740 581,487
2021-03-31 $7,868,716 658,470
2020-12-31 $10,426,853 841,554
2020-09-30 $1,819,731 174,137
2020-06-30 $6,990,000 500,000
2020-06-30 $7,322,192 523,762
2020-06-30 $1,479,084 105,800
2020-03-31 $6,101,557 518,840
2020-03-31 $6,938,400 590,000
2020-03-31 $5,782,392 491,700